| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/20/2013 | EP2569284A1 2 -aminopyridine derivatives useful as inhibitors of atr kinase |
| 03/20/2013 | EP2569280A1 Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof |
| 03/20/2013 | EP2569277A1 Substituted 8-alkoxy-2-aminotetralin derivatives, and use thereof |
| 03/20/2013 | EP2569273A1 Novel antimicrobial compounds and uses thereof |
| 03/20/2013 | EP2569267A1 Improved methods for preparing squalene |
| 03/20/2013 | EP2569014A1 Treatment methods |
| 03/20/2013 | EP2568997A2 Compositions and methods which modulate g-protein signaling for the treatment of inflammatory disorders such as asthma and allergic conjunctivitis |
| 03/20/2013 | EP2568992A2 Pharmaceutical composition comprising an algae adapted to increase the efficacy of an enzymatic inhibitor |
| 03/20/2013 | EP2568988A1 Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt |
| 03/20/2013 | EP2568987A2 Tetracycline compositions |
| 03/20/2013 | EP2568986A1 Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
| 03/20/2013 | EP2568985A1 Polymorphs of alogliptin benzoate |
| 03/20/2013 | EP2568984A1 Compounds useful as inhibitors of atr kinase |
| 03/20/2013 | EP2568983A1 Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| 03/20/2013 | EP2568982A1 Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof |
| 03/20/2013 | EP2568981A1 Association of xanthine oxidase inhibitors and statins and use thereof |
| 03/20/2013 | EP2568980A1 Injectable parasiticidal formulations of levamisole and macrocyclic lactones |
| 03/20/2013 | EP2568979A2 Ratiometric combinatorial drug delivery |
| 03/20/2013 | EP2568978A2 Cancer prevention and treatment methods based on dietary polyamine content |
| 03/20/2013 | EP2568977A1 Alcohol-resistant metoprolol-containing extended- release oral dosage forms |
| 03/20/2013 | EP2568976A2 Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses |
| 03/20/2013 | EP2568974A1 Alcohol-resistant oral pharmaceutical form |
| 03/20/2013 | EP2568973A2 Film coating composition and methods of making and using the same |
| 03/20/2013 | EP2568972A2 Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan |
| 03/20/2013 | EP2568971A1 Canagliflozin containing tablets |
| 03/20/2013 | EP2568970A2 Stable pharmaceutical formulations containing an antihistaminic |
| 03/20/2013 | EP2568967A2 Pharmaceutical compositions comprising hydromorphone and naloxone |
| 03/20/2013 | EP2568964A1 Pharmaceutical dosage form comprising one or more antiretroviral active ingredients |
| 03/20/2013 | EP2568962A1 A sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent |
| 03/20/2013 | EP2568961A2 Therapeutic liposomes and methods for producing and using the same |
| 03/20/2013 | EP2568959A2 Formulations comprising a third generation cephalosporin and clavulanic acid |
| 03/20/2013 | EP2568957A1 Pharmaceutical composition comprising cefixime and clavulanic acid derivative compound |
| 03/20/2013 | EP2568827A1 Composition for reducing absorption of dietary fat |
| 03/20/2013 | EP2568826A1 Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline |
| 03/20/2013 | EP2568812A1 Novel prolylcarboxypeptidase inhibitors |
| 03/20/2013 | EP2568811A1 Treatment of mci and alzheimer's disease |
| 03/20/2013 | EP2568810A1 Darunavir compositions |
| 03/20/2013 | EP2568809A1 Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| 03/20/2013 | EP2568807A1 Phenoxyalkyl pyridinium oxime therapeutics for treatment of organophosphate poisoning |
| 03/20/2013 | EP2568806A1 Therapeutic regimens |
| 03/20/2013 | EP2568805A1 A medical fluid, a method of treatment and use of the fluid |
| 03/20/2013 | EP2384754B1 Pharmaceutical dosage forms |
| 03/20/2013 | EP2343071B1 Pharmaceutical dosage forms |
| 03/20/2013 | EP2125795B1 Indole derivatives |
| 03/20/2013 | CN202802228U Cation organosilicon antibiosis itch-relieving medical silica gel scar sticker film |
| 03/20/2013 | CN202802226U Ketoprofen-containing gel paste |
| 03/20/2013 | CN1869056B Method of extracting and separating ginseng saponine mixture from ginseng leaf |
| 03/20/2013 | CN1606554B Beta-lactamyl vasopressin v1a antagonists |
| 03/20/2013 | CN1441841B Stimulation of cellular regeneration and differentiation in inner ear |
| 03/20/2013 | CN102985546A Combinations of TGF-beta and Cox-2 inhibitors and methods for their therapeutic application |
| 03/20/2013 | CN102985543A Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4 |
| 03/20/2013 | CN102985438A C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors |
| 03/20/2013 | CN102985432A Derivative of AMP to treat cardiac diseases |
| 03/20/2013 | CN102985426A Pyrazolo [1, 5A] pyrimidine and thieno [3, 2B] pyrimidine derivatives as IRAK4 modulators |
| 03/20/2013 | CN102985425A Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
| 03/20/2013 | CN102985424A 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases |
| 03/20/2013 | CN102985423A Crystalline forms of a purine derivative |
| 03/20/2013 | CN102985422A Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases |
| 03/20/2013 | CN102985421A Naphthridine derivatives as pi3k inhibitors for the treatment of cancer and immune - inflammatory diseases |
| 03/20/2013 | CN102985420A Cytochrome P450 inhibitors and uses thereof |
| 03/20/2013 | CN102985418A Apoptosis signal-regulating kinase inhibitors |
| 03/20/2013 | CN102985417A Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
| 03/20/2013 | CN102985415A Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders |
| 03/20/2013 | CN102985413A Tricarbonyl technetium-99m or rhenium-188 label ring RGD derivative, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagnosis or treatment of angiogenesis-related diseas |
| 03/20/2013 | CN102985412A 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia |
| 03/20/2013 | CN102985411A Imaging agents for detecting neurological disorders |
| 03/20/2013 | CN102985410A Combretastatin analogs for use in the treatment of cancer |
| 03/20/2013 | CN102985407A 8-hydroxy-quinoline derivatives |
| 03/20/2013 | CN102985405A Heterocyclic compound, and p27 kip1 degradation inhibitor |
| 03/20/2013 | CN102985402A Tranylcypromine derivatives as inhibitors of histone demethylase LSD1 and/or LSD2 |
| 03/20/2013 | CN102985138A Compositions for the treatment of gynaecological disorders |
| 03/20/2013 | CN102985112A Pharmaceutical composition for treatment and prevention of herpesvirus infections |
| 03/20/2013 | CN102985105A Nutritional Formulas Containing Synbiotics |
| 03/20/2013 | CN102985095A Immunostimulatory and vaccine compositions |
| 03/20/2013 | CN102985094A Recombinant tumor vaccine and method of producing such vaccine |
| 03/20/2013 | CN102985093A Agent for suppressing the formation of abnormal skin cells caused by exposure to light |
| 03/20/2013 | CN102985092A Synthesis of DGJNAc from D-glucuronolactone and use to inhibit alpha-N-acetylgalactosaminidases |
| 03/20/2013 | CN102985091A Compositions and methods for treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds |
| 03/20/2013 | CN102985090A 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
| 03/20/2013 | CN102985089A Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| 03/20/2013 | CN102985088A Improved treatment of renal cell carcinoma |
| 03/20/2013 | CN102985087A Tacrolimus-containing oil-in-water type creamy composition |
| 03/20/2013 | CN102985086A Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| 03/20/2013 | CN102985085A Methods for treating bipolar disorder |
| 03/20/2013 | CN102985084A Compounds for the treatment of posterior segment disorders and diseases |
| 03/20/2013 | CN102985083A Formulations of quinones for the treatment of ophthalmic diseases |
| 03/20/2013 | CN102985082A Propynylaminoindan transdermal compositions |
| 03/20/2013 | CN102985075A Canagliflozin containing tablets |
| 03/20/2013 | CN102985074A Pharmaceutical dosage form comprising one or more antiretroviral active ingredients |
| 03/20/2013 | CN102985072A Pharmaceutical compositions |
| 03/20/2013 | CN102985071A 透析前体组合物 Dialysis precursor composition |
| 03/20/2013 | CN102985070A Very low-dosed solid oral dosage forms for HRT |
| 03/20/2013 | CN102985069A Stable ready to use injectable paracetamol formulation |
| 03/20/2013 | CN102985065A Use of glabranin for stimulating hair growth |
| 03/20/2013 | CN102984945A An enantioselective process for cycloalkenyl [beta]-substituted alanines |
| 03/20/2013 | CN102984943A Improved process for a folate-targeted agent |
| 03/20/2013 | CN102984941A Compositions and methods for treatment of leukemia |
| 03/20/2013 | CN102984940A Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin |
| 03/20/2013 | CN102984937A Antimicrobial compositions |
| 03/20/2013 | CN102977413A New method for preparing micelles by compounding polymers |